Early signs of eczema, food allergies may dwell on infants’ skin
The first clues that a baby may develop eczema or food allergies could be hiding in the microscopic organisms living on their skin, according to a study led… read more.
The first clues that a baby may develop eczema or food allergies could be hiding in the microscopic organisms living on their skin, according to a study led… read more.
NICE(UK) updated recommendation their 6 August 2026 recommendation to expand the population in line with the marketing authorisation. We also updated the technology name and title to more… read more.
Three large studies together show that, although the number of people who smoke is declining, people are taking up smoking at a younger age and vaping has increased,… read more.
Insmed Incorporated announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in… read more.
For sleep-deprived nursing moms, artificial intelligence may feel like a lifeline. In fact, a new national survey from Orlando Health reveals if women ages 18 to 44 had an urgent… read more.
Emergency Medicine & Intensive Care
Nearly 500 children have been injured by e-scooters since 2019, with less than 2% reportedly wearing a helmet, and their average age just 12, shows a 3-centre study… read more.
ALK announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX) and house dust mite tablet (ACARIZAX) for… read more.
Shield Therapeutics announced the publication of the positive efficacy, tolerability and palatability results from the ferric maltol pediatric FORTIS clinical trial, comparing the safety and efficacy of ferric… read more.
JCR Pharmaceuticals announced its development plan in Japan for givinostat, a treatment for Duchenne muscular dystrophy (DMD), following consultation with the Pharmaceuticals and Medical Devices Agency (PMDA). Based… read more.
A multi-institutional study led by researchers at Children’s Hospital of Philadelphia (CHOP) found that telemedicine is becoming increasingly common for problem-based primary care, particularly for children with endocrine… read more.
Arcutis Biotherapeutics announced that the FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.
Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.05% to expand the indication for the topical treatment of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.